[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100593105":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":28,"responsibleParty":129,"collaborators":132,"id":136,"slug":137,"hasResults":138,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":20,"eligibilityCriteria":142,"healthyVolunteers":138,"sex":143,"minAge":144,"maxAge":20,"enrollmentInfo":145,"targetDuration":20,"studyType":148,"phases":149,"briefSummary":151,"conditions":152,"keywords":20,"overallStatus":31,"whyStopped":20,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":163},{"fullName":5,"class":6},"The First Affiliated Hospital with Nanjing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"CD19\u002FCD20 Dual-Target in vivo CAR-T Lentiviral","EXPERIMENTAL","Each subject will be given a single-dose CD19\u002FCD20 Dual-Target in vivo CAR-T Lentiviral product infusion at each dose level.",[13],"Biological: CD19\u002FCD20 Dual-Target in vivo CAR-T Lentiviral product",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"BIOLOGICAL","CD19\u002FCD20 Dual-Target in vivo CAR-T Lentiviral product","Prior to infusion of theCD19\u002FCD20 Dual-Target in vivo CAR-T Lentiviral product, subjects will receive bridging therapy if needed.",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":26,"email":27},"FAN Lei","CONTACT","13813976136","+86","fanlei3014@126.com",[29,50,66,82,99,115],{"facility":30,"status":31,"city":32,"state":33,"zip":34,"country":35,"countryCode":36,"cosmosGeoPoint":37,"geoPoint":42,"contacts":43},"The First Affiliated Hospital of USTC west district","RECRUITING","Hefei","Anhui","230000","China","CN",{"type":38,"coordinates":39},"Point",[40,41],117.28083,31.86389,{"lat":41,"lon":40},[44,48],{"name":45,"role":24,"phone":46,"phoneExt":26,"email":47},"Kaiyang DING","13966672170","dingkaiy@126.com",{"name":45,"role":49,"phone":20,"phoneExt":20,"email":20},"PRINCIPAL_INVESTIGATOR",{"facility":51,"status":31,"city":52,"state":53,"zip":54,"country":35,"countryCode":36,"cosmosGeoPoint":55,"geoPoint":59,"contacts":60},"Beijing Gobroad Boren Hospita","Beijing","Beijing Municipality","102206",{"type":38,"coordinates":56},[57,58],116.39723,39.9075,{"lat":58,"lon":57},[61,65],{"name":62,"role":24,"phone":63,"phoneExt":26,"email":64},"Yajing ZHANG","18601333856","23975701@qq.com",{"name":62,"role":49,"phone":20,"phoneExt":20,"email":20},{"facility":67,"status":31,"city":68,"state":69,"zip":70,"country":35,"countryCode":36,"cosmosGeoPoint":71,"geoPoint":75,"contacts":76},"The Fourth Hospital of Hebei Medical University","Shijiazhuang","Hebei","050000",{"type":38,"coordinates":72},[73,74],114.47861,38.04139,{"lat":74,"lon":73},[77,81],{"name":78,"role":24,"phone":79,"phoneExt":26,"email":80},"Haisheng LIU","13933078299","liuhs78299@163.com",{"name":78,"role":49,"phone":20,"phoneExt":20,"email":20},{"facility":83,"status":84,"city":85,"state":86,"zip":87,"country":35,"countryCode":36,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"The First Affiliated Hospital of ZHENGZHOU University","NOT_YET_RECRUITING","Zhengzhou","Henan","450000",{"type":38,"coordinates":89},[90,91],113.64861,34.75778,{"lat":91,"lon":90},[94,98],{"name":95,"role":24,"phone":96,"phoneExt":26,"email":97},"Yi Zhang","15138928971","yizhang001@163.com",{"name":95,"role":49,"phone":20,"phoneExt":20,"email":20},{"facility":100,"status":31,"city":101,"state":102,"zip":103,"country":35,"countryCode":36,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Union Hospital Tongji Medical College Huazhong University of Science and Technology","Wuhan","Hubei","430000",{"type":38,"coordinates":105},[106,107],114.26667,30.58333,{"lat":107,"lon":106},[110,114],{"name":111,"role":24,"phone":112,"phoneExt":26,"email":113},"Heng MEI","13886160811","mayheng@126.com",{"name":111,"role":49,"phone":20,"phoneExt":20,"email":20},{"facility":5,"status":31,"city":116,"state":117,"zip":118,"country":35,"countryCode":36,"cosmosGeoPoint":119,"geoPoint":123,"contacts":124},"Nanjing","Jiangsu","210029",{"type":38,"coordinates":120},[121,122],118.77778,32.06167,{"lat":122,"lon":121},[125,128],{"name":126,"role":24,"phone":25,"phoneExt":127,"email":27},"Lei FAN","+186",{"name":126,"role":49,"phone":20,"phoneExt":20,"email":20},{"type":49,"investigatorFullName":130,"investigatorTitle":131,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"Lei Fan","Director of lymphoma center",[133],{"name":134,"class":135},"Nanjing Legend Biotech Co.","INDUSTRY","100593105","phase-1-the-cd19cd20-dual-target-in-vivo-car-t-lentiviral-product-in-the-treatment-of-relapsedrefractory-b-cell-malignancies-100593105",false,"NCT07002112","The CD19\u002FCD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed\u002FRefractory B-cell Malignancies","A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19\u002FCD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed\u002FRefractory B-cell Malignancies","Inclusion Criteria:\n\n1. Subjects voluntarily participate in clinical studies; Fully informed of this study and signed informed consent; Informed consent form must be obtained prior to initiation of any study-related tests or procedures that are not part of the standard treatment for the subject's disease; Good compliance and cooperation with follow-up.\n2. Age greater than or equal to 18.\n3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n4. At least one evaluable tumor lesion.\n5. Relapsed and\u002For refractory NHL , and relapsed and\u002For refractory CLL with treatment indications\n6. Life expectancy≥ 3 months\n7. Clinical laboratory values meet screening visit criteria\n8. Adequate organ function;\n\nExclusion Criteria:\n\nSubject eligible for this study must not meet any of the following criteria:\n\n1. Prior antitumor therapy with insufficient washout period ;\n2. Prior treatment with lentiviral vector-based gene therapies;\n3. Patients who are positive for hepatitis B surface antigen (HBsAg), hepatitis B virus deoxyribonucleic acid (HBV DNA), hepatitis C antibody (HCV-Ab), hepatitis C virus ribonucleic acid (HCV RNA), and human immunodeficiency virus antibody (HIV-Ab).\n4. Known life-threatening allergic reaction, hypersensitivity reaction, or intolerance to study drug excipients and related excipients, including but not limited to DMSO; or those with a history of severe allergic reactions in the past (such as hypersensitivity reactions, or those with severe immune-related reactions such as the need for glucocorticoids to prevent anaphylaxis as assessed by the investigator).\n5. Lactating women;","ALL","18 Years",{"count":146,"type":147},30,"ESTIMATED","INTERVENTIONAL",[150],"PHASE1","A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of the CD19\u002FCD20 Dual-Target in vivo CAR-T Lentiviral product in the Treatment of Relapsed\u002FRefractory B-cell Malignancies.",[153],"Relapsed\u002FRefractory B-cell Malignancies","2026-05-11",{"date":156,"type":157},"2026-05-14","ACTUAL",{"date":159,"type":157},"2025-05-23",{"date":161,"type":147},"2029-06-30",{"name":5,"class":6},6]